CaMKII is more highly expressed in stage III and IV endometrial carcinomas when compared to stage I and II, and is associated with PCNA-labelling, clinical state, histological grade, and the presence of invasion, indicating that similar to CaMKI, CaMKII may play a role in endometrial carcinoma progression [94]. This evidence concerns the gene CAMK2G and endometrial carcinoma.